Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

TheFly reported connected January 20 that Piper Sandler raised its terms people on IBRX to $7 from $5 and maintained an Overweight rating. According to the update, U.S. ANKTIVA nett income accrued by astir 700% twelvemonth implicit twelvemonth to $113 cardinal successful 2025. Revenue is expected to scope $180 cardinal in 2026. A possible label expansion for ANKTIVA successful 2027 whitethorn beryllium supported by affirmative QUILT-2.005 data anticipated in Q4 2026, according to the firm’s encouraging interim results.

Additionally, connected January 23, ImmunityBio, Inc. (NASDAQ:IBRX) reported Phase 2 QUILT-3.078 results successful recurrent GBM. According to the studies, the longest endurance was 12 months, and the median wide endurance has not achieved, meaning that 19 retired of 23 patients are inactive living. The regimen had a tenable information profile, immunological competence was preserved, and terrible lymphopenia improved (ALC ≥1.4 ×10³/µL).

ImmunityBio, Inc. (NASDAQ:IBRX) is simply a U.S. biotechnology institution processing next‑generation immunotherapies and vaccines that heighten the earthy immune strategy to combat cancers and infectious diseases.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.